SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-24-013830
Filing Date
2024-02-12
Accepted
2024-02-12 09:00:54
Documents
1
Group Members
ANTOINE PAPIERNIKGRAZIANO SEGHEZZIHENRIJETTE RICHTERMAINA BHAMANSOFINNOVA CAPITAL VIII

Document Format Files

Seq Description Document Type Size
1 SC 13G tm245842d1_sc13g.htm SC 13G 160970
  Complete submission text file 0001104659-24-013830.txt   162787
Mailing Address 17 RUE DE SERENE PARIS I0 75008
Business Address 17 RUE DE SERENE PARIS I0 75008 33 1 53 05 41 13
Sofinnova Partners SAS (Filed by) CIK: 0001574139 (see all company filings)

IRS No.: 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Subject) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-91007 | Film No.: 24617580
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)